16 research outputs found
Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase
We evaluated the interaction between oncolytic, replication-competent
adenoviral vectors and the herpes simplex virus-1 thymidine kinase
(HSV1-tk) gene/ganciclovir (GCV) suicide system for the treatment of
malignant gliomas. We constructed a panel of replication-competent
adenoviral vectors in which the luciferase (IG.Ad5E1(+). E3Luc) or HSV1-tk
gene (IG.Ad5E1(+).E3TK) replace the M(r) 19,000 glycoprotein (gp19K)
coding sequence in the E3 region. IG.Ad5E1. IG.Ad5.ClipLuc and IG.AdApt.TK
are E1-deleted viruses that contain the luciferase or the HSV1-tk gene in
the former E1 region driven by the human cytomegalovirus promoter.
IG.Ad5.Sarcoma 1800HSA.E3Luc contains an irrelevant gene in the E1 region,
whereas the gp19K coding sequence in the E3 region is replaced by the
luciferase gene as in the replicating virus IG.Ad5E1(+).E3Luc. For in
vitro experiments, we used a panel of human glioma cell lines (U87 MG,
T98G, A172, LW5, and U251), a rat gliosarcoma cell line (9 L), and human
lung (A549) and prostate carcinoma (P3) cell lines. In vitro, GCV
sensitivity (10 microg/ml) was studied in U87 MG cells after infection at
a multiplicity of infection of 1 and 10. A s.c. U87 MG glioma xenograft
model was established in NIH-bg-nu-xid mice. Tumors of 100-150 mm(3) were
treated with a single injection of adenovirus 10(9) IU suspended in 100
microl of PBS, and GCV 100 mg/kg was administered i.p. twice daily for 7
days. The cytopathic effect of all three replication-competent adenoviral
vectors was similar to the cytopathic effect of wild-type adenovirus 5 on
all human cell lines tested, indicating that deletion of the E3 gp19K
sequences did not affect the oncolytic effect of the vectors. In vitro,
luciferase expression was the same for both E1-deleted vectors
(IG.Ad5.ClipLuc and IG.Ad5.Sarcoma 1800HSA.E3Luc), demonstrating the
strength of the internal E3 promoter even in the absence of E1A. However,
in vitro expression levels obtained with replication-competent
IG.Ad5E1(+). E3Luc were 3 log higher (allowing infection with a
Mitochondrial neurogastrointestinal encephalomyopathy caused by thymidine phosphorylase enzyme deficiency: From pathogenesis to emerging therapeutic options
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a progressive metabolic disorder caused by thymidine phosphorylase (TP) enzyme deficiency. The lack of TP results in systemic accumulation of deoxyribonucleosides thymidine (dThd) and deoxyuridine (dUrd). In these patients, clinical features include mental regression, ophthalmoplegia, and fatal gastrointestinal complications. The accumulation of nucleosides also causes imbalances in mitochondrial DNA (mtDNA) deoxyribonucleoside triphosphates (dNTPs), which may play a direct or indirect role in the mtDNA depletion/deletion abnormalities, although the exact underlying mechanism remains unknown. The available therapeutic approaches include dialysis and enzyme replacement therapy, both can only transiently reverse the biochemical imbalance. Allogeneic hematopoietic stem cell transplantation is shown to be able to restore normal enzyme activity and improve clinical manifestations in MNGIE patients. However, transplant related complications and disease progression result in a high mortality rate. New therapeutic approaches, such as adeno-associated viral vector and hematopoietic stem cell gene therapy have been tested in Tymp−/− Upp1−/− mice, a murine model for MNGIE. This review provides background information on disease manifestations of MNGIE with a focus on current management and treatment options. It also outlines the pre-clinical approaches toward future treatment of the disease
Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease
Objective: To determine the clinical features and presence in CSF of antineuronal antibodies in patients with pathologically proven autoimmune encephalitis derived from a cohort of patients with suspected Creutzfeldt-Jakob disease (CJD). Methods: The Dutch Surveillance Centre for Prion Diseases performed 384 autopsies on patients with suspected CJD over a 14-year period (1998-2011). Clinical information was collected from treating physicians. Antineuronal antibodies were tested in CSF obtained postmortem by immunohistochemistry on fresh frozen rat brain sections, by Luminex assay for the presence of wellcharacterized onconeural antibodies, and by cell-based assays for antibodies against NMDAR, GABABR1/2, GABAAR GLUR1/2, LGI1, Caspr2, and DPPX. Results: In 203 patients, a diagnosis of definite CJD was made, while in 181 a variety of other conditions were diagnosed, mainly neurodegenerative. In 22 of these 181, the neuropathologist diagnosed autoimmune encephalitis. One patient was excluded because of lack of clinical information. Inflammator
Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
Although many patients are cured from prostate cancer (PCa) by surgery only, there are still patients who will experience rising prostate-specific antigen (PSA) levels after surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic markers in PCa tissue might enable finding better treatment for those patients experiencing BCR with a high chance of metastasis. In this study, we aimed to identify altered proteins in prostate cancer tissue, and to evaluate their potential role as prognostic markers. We used two proteomics strategies to analyse 34 prostate tumours (PCa) and 33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic markers of the disease. Tissue microarray immunohistochemical staining indicated that a low percentage of positive tumour cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93)), and a low percentage of positive tumour cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-5.22)) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value for PCa
Mass spectrometric detection of antigen-specific immunoglobulin peptides in paraneoplastic patient sera
Paraneoplastic neurological syndromes (PNS) are severe immune mediated effects of cancer. The presence of IgG autoantibodies against onconeural antigens in serum is a hallmark of the disease. Multiple paraneoplastic antibodies have been described, including antibodies against HuD, Yo, amphiphysin and CV2. In this study, we test the hypothesis that primary amino-acid structures of the antigen binding part of antibodies from various individuals share common sequences that are specific for each auto-antigen.We selected 60 patients with PNS, associated with antibodies against HuD, Yo, Amp or CV2. Affinity purified IgG was separated using SDS-PAGE and IgG heavy chains were excised, trypsinized and subjected to tandem mass spectrometry. We selected masses that uniquely identified a PNS autoantibody group, and used MS/MS fragmentation spectra to obtain information on peptide sequences. Out of 19,173 unique masses, 28 immunoglobulin-derived peptides were found exclusively in samples from a single autoantibody defined PNS group.Our results confirm that specific peptide structures exist in the antigen binding site of IgG that are shared between individuals harboring autoantibodies against the same onconeural antigen. Thus, the immune response in these patients followed converging paths during the rearrangement, selection and maturation of immunoglobulin sequences. The identified peptides can be applied in the diagnosis of PNS, but these data also indicate that a similar approach in a variety of other diseases involving an immune response would have an appealing outlook
A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes
Background Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective open-label, single-arm study on sirolimus. Methods Seventeen progressive Hu-PNS patients were treated with sirolimus with an intended treatment duration of 8 weeks. Primary outcome measures were (i) functional improvement, defined as a decrease of one or more points on the modified Rankin Scale (mRS), and (ii) improvement of neurological impairment, defined as an increase of one or more points on the Edinburgh Functional Impairment Tests (EFIT). Results One patient showed improvement on both clinical scales (mRS and EFIT). This patient presented with limbic encephalitis and improved dramatically from an mRS score of 3 to mRS 1. Another patient, with subacute sensory neuronopathy, remained stable at mRS 2 and improved one point on the EFIT scale. The other patients showed no improvement on the primary outcome measures. Median survival was 21 months. Conclusion We conclude that treatment of Hu-PNS patients with sirolimus may improve or stabilize their functional disabilities and neurological impairments. However, the effects of this T cell-targeted therapy were not better than reported in trials on other immunotherapies for Hu-PNS. Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000793-20/NL
Imaging expression of adenoviral HSV1-tk suicide gene transfer using the nucleoside analogue FIRU.
Item does not contain fulltex